Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend was somehow relaxing and refreshing, given the events occurring outside your window. Now, though, the time has come to resume the usual routine of Zoom meetings, Skype calls, and deadlines. After all, the world keeps spinning. So why not give it a push with help from a cup of stimulation? Our choice today is blueberry mountain. Feel free to join us. Meanwhile, here are a few items of interest to get you going. Hope you have a swell day, and stay safe — wear a mask. …

South Africa is halting its rollout of the Covid-19 vaccine from AstraZeneca (AZN) and the University of Oxford, following a new analysis that suggests the shot “provides minimal protection” against mild disease caused by the new coronavirus variant circulating in that country, STAT writes. Two top virologists advising the government said the pause is necessary and a new process will study vaccines to try and determine that each vaccine reduces Covid hospitalizations in South Africa despite the widespread new variant there.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.